Celanese enters October with a stock near multi-year lows, a cluster of insider purchases at current prices, and short sellers adding back positions they cut aggressively through August. The tension between those two signals is the story this week.
The insider activity is hard to ignore. CFO Chuck Kyrish made three separate open-market purchases on August 14, totalling 2,300 shares at around $45.50, spending roughly $104,700 of his own money. None were executed under a 10b5-1 plan. SVP and General Counsel Ashley Duffie and SVP of Acetyls Mark Murray also bought in on August 11, neither through a pre-arranged programme. Together, the cluster of discretionary purchases from senior executives at current price levels is the clearest expression of internal conviction the data shows. The stock closed Tuesday at $44.84, below the prices those insiders paid, which means they are currently sitting on a loss.
Short interest has been moving in the opposite direction. Shorts hold roughly 5.8% of the free float, up 6.3% week on week, reversing a sharp decline from late August when positions briefly collapsed from around 9 million shares to under 5.5 million. The borrow market remains easy. Availability is at 2,403%, meaning there are far more shares available to lend than currently borrowed, and cost to borrow is only 0.47%, low by any standard even if it has risen 28% over the past week. The options market does not signal any hedging urgency either: the put/call ratio of 0.63 is fractionally below its 20-day average, and a z-score near zero points to no unusual directional bias. The lending setup tells you shorts can build positions freely and at minimal cost, which may partly explain the week's rebuild.
The Street is broadly constructive but has been trimming targets for months. Citigroup lowered its price target to $58 from $60 today while keeping its Buy rating. That follows a string of similar moves: Wells Fargo cut from $80 to $65 after Q2 results, Morgan Stanley trimmed from $72 to $58 in July, and BofA moved from $72 to $63 in late June. The direction of travel is consistently lower, even among bulls. The mean price target now stands at $63.12, implying around 40% upside from the current price. Keybanc initiated coverage earlier this month with an Overweight at $57. JP Morgan upgraded to Overweight back in May and has stayed there. Valuation is undemanding: the stock trades at roughly 7.3 times earnings and just under book value, with EV/EBITDA at 8.0 times. The 12-month forward EPS growth factor scores in the 80th percentile, but near-term earnings momentum ranks in the low 30s, reflecting the gap between recovery hopes and current results. The analyst recommendation divergence factor scores in the 94th percentile, suggesting the Street is more split on direction than usual for this name.
The bear case is grounded in real data. Demand for non-tow acetyl products in the Western Hemisphere has reportedly fallen to the lowest level in roughly two decades. China and European automotive volumes remain weak. The most recent quarterly EBITDA came in at $326 million, which beat expectations but still represented a 2% year-on-year sales decline to $1.44 billion. The bull case requires a macro recovery in automotive and electronics that has not yet arrived in the numbers. One signal worth noting from the ORTEX alt data layer: retail attention, measured by Wikipedia pageviews, is running at a z-score of 2.1 versus the stock's own 90-day history, the highest attention reading in recent months. That is a gauge of interest, not a revenue indicator.
Peer chemicals names had a rough week too. TROX fell 9.3% and OLN dropped 8.3%, while DOW and LYB each lost around 2%. CE fell 5.5% on the week, tracking the sector rather than breaking from it. With Q3 results due November 5, the next six weeks will test whether the insider buyers or the short rebuilders have better read the inflection point.
See the live data behind this article on ORTEX.
Open CE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
